CN Mobile Logo



Some Sarcomas May Require Long-Term Follow-Up

Although rare, long-term recurrence of soft-tissue sarcoma is possible, and patients with retroperitoneal, very large sarcomas, or high-grade disease should undergo long-term follow-up to detect late disease recurrence.


Imatinib had no impact on failure-free or overall survival in patients with gastrointestinal stromal tumor, but it did have an effect on relapse-free survival.

A treatment strategy including dose intensification with interval compression, use of the most active agents available, and the use of irinotecan as a radiation sensitizer led to a promising event-free survival rate in certain patients with metastatic rhabdomyosarcoma.

The FDA announced the approval of trabectedin (Yondelis) for the treatment of liposarcoma and leiomyosarcoma that is either unresectable or has metastasized.

The US Food and Drug Administration has granted a Priority Review designation to eribulin for the treatment of inoperable soft-tissue sarcoma.

Vascular reconstruction increases morbidity in sarcoma patients undergoing resection vs those without vascular procedures, but oncologic outcomes are similar.

Trabectedin was found to offer superior disease control to dacarbazine in patients with advanced liposarcoma and leiomyosarcoma.

Preoperative chemotherapy, both with or without concurrent radiotherapy, is feasible among patients with localized, high-risk soft-tissue sarcoma, according to a new phase III trial.


Subscribe to Sarcoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.